Junshi Biosciences announced that its Phase 3 NEOTORCH study of toripalimab combined with chemotherapy for resectable stage II-III non-small cell lung cancer (NSCLC) met primary endpoints for event-free survival and major pathological response. This positive result supports their plan to submit a supplemental new drug application to expand toripalimab's approval for perioperative treatment to include stage II-III NSCLC. The study showed significant improvements in survival and tumor response compared to chemotherapy alone, marking an important advance in lung cancer treatment. Toripalimab is already approved for stage III NSCLC perioperative treatment in China and several other indications globally.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
Gooch & Housego, a UK-listed photonics company specializing in precision optics for aerospace and defence, has agreed to a £345.6 million takeover by US private equity firm Arlington Capital Partners. The offer values the company at a 41.3% premium t...
Aave DAO has proposed an innovative mobile app that integrates fiat currency deposits, self-custody, and decentralized finance (DeFi) lending in one platform. This app allows users to convert fiat to stablecoins and earn yields without needing extern...
Analysts expect Netflix to report $12.6 billion in revenue for Q2 and $51.3 billion for the full year 2026. The operating margin forecast has been revised down from 33% to 32% due to anticipated higher expenses, with an expected operating profit of $...
